In yet another deal to diversify its portfolio, BioNTech has entered into a licensing and collaboration agreement with Duality Biologics to develop, manufacture and commercialise two antibody-drug conjugate (ADC) therapies. The agreement, which involves a US$170 M upfront payment and up to US$1.5 B in milestones, will provide BioNTech with access to DualityBio’s topoisomerase-1 inhibitor-based cancer ADCs, DB-1303 and DB-1311. The deal was announced on the same day that Takeda invested in Innate Pharma’s ADC modalities for celiac disease, as the field gains further traction due to its transformative potential in oncology.